中文

Legend Biotech falls 16% as it tempers expectations for Carvykti sales

By · AI-assisted, human-reviewed and edited · · 13 sources · Fact-checked · 4 min read

Why is Legend stock down today?

Legend Biotech fell 16% after finance chief Carlos Santos said analysts' forecasts for its multiple myeloma therapy Carvykti, sold with Johnson & Johnson, sit at the high end of the company's own scenarios for the fourth quarter and 2027, citing slower US uptake earlier in treatment and delayed launches abroad. The flat US sales behind the comment had been public since J&J's Oct 13 report, after which the shares had risen 36%.

What it means

What changed
Management said analysts' Carvykti sales forecasts for the fourth quarter and 2027 sit at the high end of its own scenarios.
What hasn't changed
Legend still expects double-digit global Carvykti growth in 2027, stayed profitable, and raised its fourth-quarter gross-margin outlook.
Next · Jan 26, 2027 (J&J's results)
J&J's fourth-quarter results, the next report of Carvykti's US and international sales.
Move
▼ 16%
Price
$24.29 → $20.41
Value lost
~$753M
Carvykti sales, Q3
~$710M, +36%
US sales vs Q2
$472M, unchanged
Q3 net income
$51.7M

Prices: Yahoo Finance and CNBC (Nasdaq close, ADS), Nov 10, 2026 · Company data: 6-K with the statements to Sep 30, 2026, filed Nov 10, 2026, Sep 30, 2026 · What these numbers mean

Closing prices: $20.41 on Nov 10, 2026, against $24.29 on Nov 9 (Yahoo Finance and CNBC; Stock Analysis shows $20.39). Prices are for American depositary shares (ADS); one ADS represents two ordinary shares. Market value lost is our estimate, using 387,938,033 ordinary shares at Sep 30, 2026 (193,969,017 ADS equivalents).

Snapshot at the Nov 10, 2026 close

Enterprise value
$3.2B†
Price/sales
2.9×
P/E
n/m
Revenue growth
n/m
Net cash
$808M†

Our calculation from the company's filings (latest: 6-K with the statements to Sep 30, 2026, filed Nov 10, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $20.41 (Yahoo Finance and CNBC (Nasdaq close, ADS)); 194.0 million shares (ADS equivalents: 387,938,033 ordinary shares at Sep 30, 2026 (6-K filed Nov 10, 2026, Note 11) divided by 2; one ADS represents two ordinary shares (2025 Form 20-F)). n/m = not meaningful (e.g. negative earnings). † Debt excludes IFRS 16 lease liabilities; debt here is the collaboration interest-bearing advanced funding from Janssen.

Legend (LEGN) closing price, Oct 12, 2026 to Nov 10, 2026: from a peak of $24.29 on Nov 9 to $20.41 (-16%).
Price data
Legend closing prices
DateClose
Oct 12, 2026$17.80
Oct 13, 2026$17.88
Oct 14, 2026$19.04
Oct 15, 2026$19.80
Oct 16, 2026$18.48
Oct 19, 2026$18.65
Oct 20, 2026$19.01
Oct 21, 2026$18.63
Oct 22, 2026$18.90
Oct 23, 2026$19.27
Oct 26, 2026$20.39
Oct 27, 2026$21.56
Oct 28, 2026$22.53
Oct 29, 2026$22.30
Oct 30, 2026$21.63
Nov 2, 2026$21.10
Nov 3, 2026$21.48
Nov 4, 2026$22.77
Nov 5, 2026$22.54
Nov 6, 2026$23.40
Nov 9, 2026$24.29
Nov 10, 2026$20.41

What happened

Legend Biotech develops and sells Carvykti with Johnson & Johnson, which books most of the sales; the two share the profits. Carvykti is a one-time CAR-T treatment made from a patient’s own modified immune cells for multiple myeloma, a blood cancer. Legend reported third-quarter results before Tuesday’s open.

  • The sales figures were already known. J&J’s Oct 13 report showed Carvykti sales of $710 million in the quarter, up 36% from a year earlier: $472 million in the US, the same as in the second quarter, and $238 million elsewhere, up from $185 million. Legend’s shares rose 36% from their Oct 12 close to Monday’s (Yahoo Finance closes; our calculation).
  • The new part was the outlook. Finance chief Carlos Santos said on the call that “the sales consensus is at the higher end of the range of scenarios that we’re actually seeing” for the fourth quarter, and that the consensus for 2027 “would be at the higher end of the scenarios that we’re currently anticipating.” He cited delayed launches outside the US and “a slower earlier line share growth in the US than we had previously anticipated,” meaning slower gains among patients treated after fewer previous regimens. He said Legend doesn’t give guidance and gave no dollar amounts, and that it still expects double-digit Carvykti growth in 2027 (Earnings Whispers transcript).
  • Legend made a profit for the second quarter in a row: its quarterly releases show net income of $51.7 million, after $33.2 million in the second quarter and a $54.3 million loss in the first. The quarter included a $24 million one-time credit from share-based pay, Santos said (the release’s reconciliation shows share-based pay as a net credit of $9.6 million for the quarter); excluding it, operating profit would have been $22.8 million (our calculation: $46.8 million minus $24 million, before tax). Santos said gross margin on net product sales reached 58%, above the company’s expectation in the low-50% range, and raised the fourth-quarter outlook to “the high 50% range.”

The shares closed down 16.0% at $20.41, from $24.29 on Monday (Yahoo Finance and CNBC), about $753 million of market value (our estimate). The S&P 500 fell 0.4% and the SPDR S&P Biotech ETF (XBI) 1.2% (CNBC). The shares were down about 6% this year (Yahoo Finance closes; our calculation).

Carvykti sales by quarter, US and international ($M)

US sales were $472 million in both the second and third quarters of 2026, while international sales kept rising. J&J reported the third quarter on Oct 13.

US ($M)0200400600Q1 2025: $318MQ2 2025: $358MQ3 2025: $396MQ4 2025: $420MQ1 2026: $433MQ2 2026: $472MQ3 2026: $472MInternational ($M)0200400600Q1 2025: $51MQ2 2025: $81MQ3 2025: $128MQ4 2025: $135MQ1 2026: $164MQ2 2026: $185MQ3 2026: $238MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026US ($M)0200400600Q1 2025: $318MQ2 2025: $358MQ3 2025: $396MQ4 2025: $420MQ1 2026: $433MQ2 2026: $472MQ3 2026: $472MInternational ($M)0200400600Q1 2025: $51MQ2 2025: $81MQ3 2025: $128MQ4 2025: $135MQ1 2026: $164MQ2 2026: $185MQ3 2026: $238MQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
Johnson & Johnson sales reports (8-K Exhibit 99.2): Q1 and Q2 2025 derived from nine-month and half-year totals, Q1 2026 from half-year less Q2 (our calculation).
Show the data table
Quarter US ($M) International ($M)
Q1 2025 318 51
Q2 2025 358 81
Q3 2025 396 128
Q4 2025 420 135
Q1 2026 433 164
Q2 2026 472 185
Q3 2026 472 238

Why the market reacted this way

The flat US quarter had been public for four weeks, and the shares rose after it; Tuesday’s fall came the day management said the market’s forecasts look high against its own planning.

  • Santos tempered sales expectations without issuing formal guidance: he said analysts’ fourth-quarter and 2027 forecasts were at the high end of Legend’s scenarios.
  • The US is where earlier use was supposed to drive growth. Carvykti’s label was expanded in 2024 to allow use earlier in treatment. Alan Bash, president of the Carvykti business, said patients receiving it after one or two previous regimens made up 50% of its US cell-collection volume in the third quarter, up from 41% in the first, but also pointed to “strong uptake” of bispecific antibodies, another type of myeloma drug, in earlier lines, calling it “an increasing competitive space.”
  • Part of the quarter’s profit was a one-off: the $24 million share-based pay credit, which Santos called one-time.

Does this change Legend’s future?

What did NOT change

Sales outside the US grew 29% from the second quarter, Legend reported about $853 million in cash, cash equivalents and time deposits at Sep 30, and it still expects double-digit global Carvykti growth in 2027. Updated National Comprehensive Cancer Network guidelines recommend referral to a T-cell therapy center when multiple myeloma first returns, the release says.

What DID change

The company has now said that analysts’ forecasts for the fourth quarter and 2027 sit at the high end of its own scenarios, after US sales were flat from one quarter to the next.

Our read

Our interpretation is that investors marked down the growth they had been paying for after the October run-up. J&J’s fourth-quarter report on Jan 26 will show whether US sales grow again.

The other view

Chief executive Ingrid Zhang said she sees peak potential of more than $5 billion for the Carvykti franchise, and finance chief Carlos Santos said the company remains "really very confident in the long-term growth outlook" for the therapy.

Source: Earnings Whispers: Legend Biotech Q3 2026 earnings call transcript, Nov 10

What to watch next

Jan 26, 2027
J&J's fourth-quarter results, which report Carvykti's US and international sales before Legend does.
Early 2027 (expected)
Legend's fourth-quarter results and any update to its 2027 view, after the finance chief said analysts' forecasts sit at the high end of its scenarios.

Quick questions

What is Carvykti?

A CAR-T therapy for multiple myeloma, a blood cancer: a patient's own immune cells are modified to attack the cancer and given back in a single infusion. It was first approved in the US in 2022 for patients who had already tried several treatments, and its label was expanded in 2024 to allow use earlier in treatment.

How does Legend share Carvykti with J&J?

J&J (through Janssen) books most of the sales. The two split Carvykti's profits and costs equally outside Greater China; in Greater China Legend bears or keeps 70%. Legend recorded $353.2 million of collaboration revenue from Carvykti in the third quarter and reports the related costs separately, so that revenue is not its profit.

Was this Legend's worst day?

Not at the close. Coverage said the shares were on track for their worst day ever while they were down about 18% during trading, but they closed down 16.0%, less than the 16.7% fall on Jun 18, 2026 (Yahoo Finance closes; our calculation).

About Legend: Website (external site)Investor relations (external site)SEC filings (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.